Summary
- Legend Biotech and partner Johnson & Johnson announced positive topline results from the CARTITUDE-4 trial of Carvykti last week.
- Positive results were expected and the market was not impressed either as no data was mentioned in the press release.
- The two companies will present the data at a medical conference and we will likely see very high response rates, significantly improved progression-free survival, and acceptable safety and tolerability.
- Net sales of Carvykti were flat sequentially in the fourth quarter as partner J&J keeps working to expand manufacturing capacity and treatment center network.
For further details see:
Legend Biotech: CARTITUDE-4 Study A Success